Wegovy is a once-weekly injection approved by the U.S. Food and Drug Administration (FDA) to treat obesity in people 12 and ...

A collection of studies presented at a recent American Heart Association (AHA) conference has confirmed the heart health benefits provided by the new anti-obesity drugs, semaglutide and tirzepatide, ...

If you are someone who has recently managed to shed your extra weight with the help of a new blockbuster GLP-1 drug then you ...

So, you have managed to shed 30 pounds with the help of one of the new blockbuster GLP-1 drugs, but as the holidays near you ...

In a new analysis of national data, researchers at the Richard A. and Susan F. Smith Center for Outcomes Research at Beth ...

LLY's recent sell-off presents a buying opportunity for savvy investors, with strong growth potential in the GLP-1 market ...

Unlike scores of people who scrambled for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, Danielle ...

We recently compiled a list of the Jim Cramer on Nvidia Plus Other Stocks. In this article, we are going to take a look at ...

In 2024, coverage for obesity drugs increased to 44% among employers with 500 or more workers, compared to 41% last year, the ...

In today’s health headlines, can GLP-1 drugs reverse prediabetes? Plus, how to reduce food noise and stick to weight loss ...

GLP-1 RAs to assist with weight loss have exploded in popularity. Researchers are working to identify which patients will ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a lower risk for venous thromboembolism (VTE).